Is there a role for beta-blockers in hypertensive diabetic patients?

Diabet Med. 1994 Mar;11(2):137-44. doi: 10.1111/j.1464-5491.1994.tb02009.x.


Clinical trials have not yet produced long-term primary prevention data on the effects of angiotensin converting enzyme inhibitors, calcium antagonists or alpha-blockers on cardiovascular complications and sudden death in hypertensive patients. Large-scale secondary preventive studies on calcium antagonists have been disappointing. In contrast, beta-blockers have an established role in cardioprotection both in primary and secondary preventive studies and there is evidence to show that the cardioprotective effect of beta-blockers is even greater in the diabetic population. Furthermore, this favourable impact of beta-blockers was achieved despite diabetic patients having a worse risk factor profile and poorer prognosis. In this review the use of beta-blockers in diabetic patients will be discussed and their impact on coronary artery disease described.

Publication types

  • Comparative Study
  • Review

MeSH terms

  • Adrenergic beta-Antagonists / therapeutic use*
  • Blood Glucose / drug effects
  • Blood Glucose / metabolism
  • Calcium Channel Blockers / therapeutic use
  • Cardiotonic Agents / therapeutic use
  • Clinical Trials as Topic
  • Diabetes Complications*
  • Diabetes Mellitus / blood
  • Diabetes Mellitus / drug therapy
  • Follow-Up Studies
  • Humans
  • Hypertension / complications
  • Hypertension / drug therapy*
  • Hypoglycemia / chemically induced
  • Insulin / adverse effects
  • Time Factors


  • Adrenergic beta-Antagonists
  • Blood Glucose
  • Calcium Channel Blockers
  • Cardiotonic Agents
  • Insulin